

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

**POLL RESULTS OF
THE 2024 ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025;
AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) is pleased to announce that the poll results of the 2024 annual general meeting (the “**AGM**”) of the Company was convened at 1:00 p.m. on Thursday, June 26, 2025 at 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC. References are made to the notice of the AGM and the circular of the Company dated May 29, 2025 (the “**Circular**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF 2024 ANNUAL GENERAL MEETING

The AGM was convened by the Board and chaired by Dr. Wu Yusheng, the Chairman of the Board. All of the Directors, namely, Dr. Wu Yusheng, Dr. Li Jun, Dr. Gu Eric Hong, Dr. Jiang Mingyu, Dr. Meng Xiaoying, Mr. He Chao, Mr. Zhang Senquan, Dr. Leng Yuting, Dr. Xu Wenqing and Dr. Shen Xiuhua attended the AGM in person or by electronics means. The convening of and the procedures for holding the AGM and the voting procedures at the AGM were in compliance with the requirements of the PRC Company Law and the Articles of Association. The poll results of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
1.	Report of the Directors for the year 2024.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
2.	Report of the Board of Supervisors for the year 2024.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
3.	Annual report for the year 2024.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
4.	Audited financial statements for the year 2024.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
5.	Remuneration of the Directors and the Supervisors for the year 2025.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
6.	Appointment of Dr. Zhu Xiangyang as a non-executive Director.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
7.	Re-appointment of Ernst & Young as the auditors and to authorize the Board to fix their remuneration.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
8.	Profit distribution plan for the year 2024.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
Special Resolutions		Number of votes (%)		
		For	Against	Abstain
9.	Issue Mandate to issue Shares.	154,099,757 (95.52%)	7,211,765 (4.47%)	14,000 (0.01%)
10.	Repurchase Mandate to repurchase H Shares.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)
11.	Proposed amendments to the Articles of Association.	161,311,522 (99.99%)	0 (0.00%)	14,000 (0.01%)

Note: All percentages are rounded up to two decimal places.

Please refer to the Circular for details of each of the above resolutions.

As more than half of the votes were cast in favour of ordinary resolutions (1) to (8) and more than two thirds of the votes were cast in favour of special resolutions (9) to (11), the above ordinary resolutions (1) to (8) and special resolutions (9) to (11) were duly passed at the AGM by way of poll by the Shareholders. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

As at the date of the AGM, the total number of issued Shares was 370,835,818 Shares, comprising 366,227,818 H Shares and 4,608,000 Unlisted Shares. The holders of all such Shares were entitled to attend and vote for or against or abstain from all the resolutions proposed at the AGM. To the best of the Director's knowledge, information and belief of the Company, there were no Shares entitling Shareholders to attend the AGM and abstain from voting in favor of the resolutions pursuant to the Rule 13.40 of the Listing Rules and none of the Shareholders are required to abstain from voting at the AGM pursuant to the Listing Rules. No Shareholders have stated their intention in the Circular to vote against any resolutions or to abstain from voting at the AGM. There were no Shares actually voted but excluded from calculating the poll results of the resolutions proposed at the AGM. As of the date of the AGM, there were (i) no H Shares repurchased and held by the

Company in treasury (“**Treasury Shares**”) (including any Treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of the Treasury Shares have been exercised at the AGM; and (ii) no repurchased Shares and therefore no Shares are pending cancellation and should be excluded from the total number of issued Shares entitled to attend and vote on all the resolutions at the AGM.

The Shareholders or their proxies present at the AGM held 161,325,522 Shares with voting rights in aggregate, representing approximately 43.50% of the total number of issued Shares as of the date of the AGM.

APPOINTMENT OF DR. ZHU XIANGYANG AS NON-EXECUTIVE DIRECTOR

The proposed resolution on the appointment of Dr. Zhu Xiangyang (朱向陽) (“**Dr. Zhu**”) as a non-executive Director was duly passed at the AGM. The Board is pleased to announce the appointment of Dr. Zhu as a non-executive Director with effect from the conclusion of the AGM.

The biographical details and other information of Dr. Zhu as required under Rule 13.51(2) of the Listing Rules are set out in the Circular. Save as disclosed in the Circular, as at the date of this announcement, Dr. Zhu does not hold any other positions with the Group, nor did he hold any other directorships, major appointments or professional qualifications in the last three years in public companies the securities of which are listed on any securities markets in Hong Kong or overseas. Further, as at the date of this announcement, Dr. Zhu has no relationship with any other Directors, Supervisors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company, nor does he have any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Zhu confirmed that there has been no change in his biographical details between the date of the Circular and the date of this announcement.

The Company has entered into a service contract with Dr. Zhu. He will serve until the end on the expiration of the term of office of the second session of the Board.

The Board would like to extend its warmest welcome to Dr. Zhu to join the Board.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, June 26, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Dr. MENG Xiaoying, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.